Folfox regimen (oxaliplatin, fluorouracil and leucovorin)
Pichon Riviere A, Augustovski F, Regueiro A, Garcia Marti S, Glujovsky D
Record ID 32005000646
Spanish
Authors' objectives:
This study aims to summarise the available evidence on the use of the Folfox regimen (oxaliplatin, fluorouracil and leucovorin) for metastatic colon or rectum cancer patients.
Authors' results and conclusions:
FOLFOX scheme adds oxaliplatin to the standard 5-FU/LV regimen. Oxaliplatin is a new third-generation platinum analogue, approved by the FDA in 2002 as second line treatment for metastatic colon or rectum cancer patients. At the beginning of 2004, the FDA approved its use in combination with 5-FU/LV as first line treatment for advanced colorectal cancer, based on data from randomized clinical trials which showed that patients with advanced colorectal cancer treated with oxaliplatin in combination with 5-FU/LV as first line chemotherapy had a statistically significant improvement, close to 5 months, in mean survival time with respect to those patients treated with FU/LV + Irinotecan (19.5 months vs 15 months). These results are also better than those observed with the standard 5-FU/LV regimen (mean survival 11 months).
Authors' recommendations:
Several trials have demonstrated that the addition of oxaliplatin to the standard 5 FU/LV regimen doubles the response to treatment and increases survival without disease progression. As a consequence, the effectiveness of FOLFOX has been adequately documented. The controversial aspect of the introduction of this technology is in relation to its cost-effectiveness and cost-usefulness due to the treatment's high marginal costs and the patient s prognosis, since, even with significant advances, the new therapies for advanced colorectal cancer are still palliative treatments.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
http://www.iecs.org.ar/
Year Published:
2004
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Drug Administration Schedule
- Antineoplastic Combined Chemotherapy Protocols
- Fluorouracil
- Leucovorin
- Neoplasms
- Organoplatinum Compounds
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.